Global Long Acting Injectable Anti-psychotic Market: Size, Trends & Forecasts (2017-2021)

Apr 11, 2017 Mark

Press Release (ePRNews.com) - DELHI, India - Apr 11, 2017 - The report entitled “Global Long Acting Injectable Anti-psychotic Market: Size, Trends & Forecasts (2017-2021)”, provides analysis of the global injectable anti-psychotic market, with detailed analysis of market size and growth, and segmentation of the industry.

Under competitive landscape, different products in the long acting injectable anti-psychotic market have been compared on the basis of different parameters such as dosing frequency, patent expiry, injection sites, label, storage, needles and available strengths. Also, a financial comparison of long acting injectable market players in the US has been done.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global long acting injectable anti-psychotic market has also been forecasted for the years 2017-2021, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Johnson & Johnson, Eli Lily and Company, Alkermes Public Limited Company and Lundbeck are some of the key players operating in the global long acting injectable anti-psychotic market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.

Country Coverage

The US

Company Coverage

Johnson & Johnson
Eli Lily and Company
Alkeremes Public Limited Company
Lundbeck

Executive Summary 

Anti-psychotic refers to a class of medicine used for the treatment of psychosis and various other emotional and mental conditions. Psychosis consist of delusions, hallucinations, paranoia and disordered thought. It is a condition in which a person experiences thought disorder and personality changes. Long acting injectable anti-psychotics are a sub type of antipsychotics which were primarily developed to improve the treatment of schizophrenia.

The global long acting injectable anti-psychotic market can be studied on the basis of different products and on the basis of prescription. These products are different types of long acting injectable anti-psychotic namely Invega Sustenna/ Trinza, Risperdal Consta, Abilify Maintena, Zyprexa, Aristada and many more.

The global long acting injectable anti-psychotic market is expected to increase at a healthy rate during the forecast period (2017-2021). The global long acting injectable anti-psychotic market is supported by various growth drivers, such as increasing cases of schizophrenia, rising number of bipolar disorder patients and non adherence to oral anti-psychotic.

However, side effect associated with anti-psychotic and patent expiry of some of the leading brands are some of the challenges faced by the market. Aging dernography, grant of approval to Trevicta in European Commission, third party proprietary technologies and label expansion of Abilify Maintena are some of the latest trends in the global long acting injectable anti-psychotic market.

List of Figures:

Figure 1: Psychiatric Disorder

Figure 2: Global Anti-psychotic Market by Value; 2011-2016 (US$ Billion)

Figure 3: Global Anti-psychotic  Market by Value; 2017-2021 (US$ Billion)

Figure 4: Global Anti-psychotic Market by Products; 2016

Figure 5: Global Anti-psychotic Market by Prescription; 2016

Figure 6: Global Long Acting Injectable Anti-psychotic  Market by Value; 2015-2021 (US$ Billion)

Figure 7: Global Long Acting Injectable Anti-psychotic Market Value by Product; 2016

Figure 8: Global Long Acting Injectable  Anti-psychotic Market Volume by Products; 2016

Figure 9: Global Long Acting Injectable Anti-psychotic Market by Region; 2016

Figure 10: Global Abilify Maintena Market by Value; 2015-2021 ( US$ Million)

Figure 11: Global Aristada Market by Value; 2015-2021 (US$ Million)

Figure 12: Global Invega Sustenna Market by Value; 2015-2021  (US$ Billion)

Figure 13: Global Risperdal Consta Market by Value; 2015-2021(US$ Million)

Figure 14: Global Zyprexa Market by Value; 2016-2021(US$ Million)

Figure 15: Global Zyprexa Market by Region; 2016

Figure 16: The US Long Acting Injectable Anti-psychotic  Market by Value 2016-2021 (US$ Billion)

Figure 17: Schizophrenia Patients in the US;2015-2025 (‘000)

Figure 18: Bipolar Disorder Patients in the US; 2017-2025 (‘000)

Figure 19: Global Population (65 years and Above); 2011-2015 (Million)

Figure 20: US Long Acting Injectable Antipsychotic  Market by Players; 2016

Figure 21: Johnson & Johnson Sales; 2012-2016 (US$ Billion)

Figure 22: Johnson & Johnson Sales by Segments; 2016

Figure 23: Eli Lily and Company Revenues; 2012-2016 (US$ Billion)

Figure 24: Eli Lily and Company Revenues by Segments; 2016

Figure 25: Alkermes Revenues; 2012-2016 (US$ Million)

Figure 26: Alkermes  Revenues by Region; 2016

Figure 27: Lundbeck Revenues; 2012-2016 (US$ Billion)

Figure 28: Lundbeck Revenues by Products; 2016

Table 1: Side Effects of Injectable Anti-psychotic

Table 2: Antipsychotic Patent Expiry Dates

Table 3: Global Long Acting Injectable Antipsychotic Market Products Compariso

For further details, kindly visit :

http://www.daedal-research.com/global-long-acting-injecta…

Rajeev Kumar

(Business Development Manager)

Address:  36 SFS Flats

Paschim Vihar

New Delhi-110063

Mobile: +91-9811715635

Tel: +91-120-4553017

Mail ID – info@daedal-research.com

Source : Azoth Analytics Follow on Google News
CATEGORIES : Reports
SHARE :  

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login

DISCLAIMER

If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.